We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Intelligent Searching Tool Enables Biochemical Lead Identification and Patent Fortification

By LabMedica International staff writers
Posted on 29 Jan 2013
Print article
A new intelligent database searching system provides virtual screening to identify biologically active molecules for a broad range of applications.

Cresset Group (Welwyn Garden City, UK) completes its Cresset proV10 suite with the relaunch of its highly successful FieldScreen system as “blazeV10” for ligand based virtual screening. Based on the shape and electrostatic character of known ligands, blazeV10 rapidly searches large chemical collections for molecules with similar properties, returning diverse new leads. This makes it a powerful tool for patent fortification and compound reprofiling.

blazeV10 is used to find biologically active molecules in a broad range of situations across the pharmaceutical, agrochemical, and fine chemical industries. Performing a virtual screen with blazeV10 before a wet screening run can dramatically increase the hit rate, cutting costs and speeding up the discovery process. Applying blazeV10 to HTS results identifies molecules, which falsely failed the biological assay, rescuing them for further investigation. Using blazeV10 on compounds of known biological activity provides insights into off-target effects. Employing blazeV10 to search databases of known drugs identifies potential reprofiling opportunities. Cresset consultants use blazeV10 to advise clients on how to strengthen their patent position by identifying structurally diverse compounds that could be potential fast followers.

“The relaunch of one of our leading applications as blazeV10 completes the rebranding of the Cresset range of software for molecular design and discovery. blazeV10, sparkV10, torchV10, and forgeV10 are outstanding tools that help chemists design and discover the best new active molecules for life science research,” said Dr. Robert Scoffin, CEO of Cresset.

blazeV10 is operated through a simple web based wizard like interface or as a series of command line applications and is available as software for installation, software as a service running on cloud hardware, or through consultancy with Cresset’s project services team.

Related Links:

Cresset Group, Ltd.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.